首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >Chinese Medicine Injection Shuanghuanglian for Treatment of Acute Upper Respiratory Tract Infection: A Systematic Review of Randomized Controlled Trials
【24h】

Chinese Medicine Injection Shuanghuanglian for Treatment of Acute Upper Respiratory Tract Infection: A Systematic Review of Randomized Controlled Trials

机译:中药双黄连注射液治疗急性上呼吸道感染:随机对照试验的系统评价

获取原文
获取原文并翻译 | 示例
           

摘要

Acute upper respiratory tract infections (AURTIs) are the illnesses caused by an acute infection with various viruses and bacteria involving the upper respiratory tract. Shuanghuanglian (SHL) injection, a Chinese medicine intravenous preparation extracted from honeysuckle, Scutellaria baicalensis, and fructus forsythiae, is commonly used to treat AURTIs. Although it is used largely in Chinese hospitals, there is no substantial evidence to demonstrate its clinical effect on AURTIs. We conducted a systematic review to evaluate the effectiveness and safety of Shuanghuanglian injection for the treatment of acute upper respiratory tract infections.
机译:急性上呼吸道感染(AURTIs)是由涉及上呼吸道的各种病毒和细菌的急性感染引起的疾病。双黄连注射液是从金银花,黄S和连翘中提取的中药静脉注射制剂,通常用于治疗AURTIs。尽管它在中国的医院中广泛使用,但没有实质性证据证明其对AURTIs有临床作用。我们进行了系统评价,以评估双黄连注射液治疗急性上呼吸道感染的有效性和安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号